Association Between Markers of Vulnerability for Cannabis-Related Harms and Source of Supply: Secondary Analysis of a Representative Population Survey.
Canada
cannabis
cannabis policy
harms
legalization
marijuana
public health
Journal
Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
pubmed:
29
9
2022
medline:
11
2
2023
entrez:
28
9
2022
Statut:
ppublish
Résumé
In 2018, the sale of non-medical cannabis was authorized in the province of Quebec in Canada, within a public monopoly under the Société Québécoise du Cannabis (SQDC). The objective of this study was to offer a description of the cannabis-using population regarding the sources of cannabis supply and to explore whether at-risk individuals are purchasing cannabis at SQDC. We used data from a cross-sectional, representative population survey (age >18 years, The vulnerability profiles of SQDC consumers (47.8%) and those acquiring their cannabis elsewhere (52.2%) were similar in terms of frequency of cannabis use (adjusted odds ratio [aOR] = 0.46; 95% confidence interval [CI] = 0.12-1.67), motivation to use (aOR = 0.62; 95% CI = 0.16-2.46), concomitant consumption of other substances (aOR = 0.80; 95% CI = 0.14-4.75), cannabis-impaired driving behaviours (aOR = 0.93; 95% CI = 0.26-3.36), psychological distress (aOR = 0.99; 95% CI = 0.26-3.79), and problematic cannabis use (aOR = 0.46; 95% CI = 0.13-1.64). However, SQDC consumers were more likely to be aware of the cannabinoid content of the product purchased compared to those who acquired their cannabis from other sources (aOR = 4.12; 95% CI = 1.10-15.40). No association was detected between the source of cannabis supply and potential vulnerability indicators of cannabis-related harms, but SQDC consumers were more aware of the cannabinoid content of the products purchased. These results suggest that the regulated government supply in Quebec is reaching a substantial portion of those with potential high vulnerability to harm. Whether this knowledge translates into a reduction in the negative consequences related to consumption is still to be determined.
Identifiants
pubmed: 36168206
doi: 10.1177/07067437221128470
pmc: PMC9923133
doi:
Substances chimiques
Cannabinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-118Références
Addiction. 2021 May;116(5):1000-1010
pubmed: 33160291
Am J Psychiatry. 2022 Feb;179(2):98-109
pubmed: 34875873
Tob Control. 2010 Oct;19(5):423-30
pubmed: 20876078
Arch Intern Med. 2007 Feb 12;167(3):221-8
pubmed: 17296876
Am J Public Health. 2014 Jun;104(6):1021-8
pubmed: 24825201
Brain. 2012 Jul;135(Pt 7):2245-55
pubmed: 22669080
CMAJ. 2017 Jul 24;189(29):E971-E972
pubmed: 28739851
J Stud Alcohol Drugs. 2011 Jan;72(1):86-95
pubmed: 21138715
Addict Behav Rep. 2019 May 10;10:100189
pubmed: 31193263
Addict Behav. 2019 Dec;99:106102
pubmed: 31473571
J Med Toxicol. 2017 Mar;13(1):71-87
pubmed: 28000146
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Addiction. 2016 Apr;111(4):653-62
pubmed: 26598973
Drug Alcohol Depend. 2021 Aug 1;225:108794
pubmed: 34098382
Br J Clin Pharmacol. 2018 Nov;84(11):2468-2476
pubmed: 29953631
Int J Drug Policy. 2016 Aug;34:1-4
pubmed: 27198553
Psychol Addict Behav. 2015 Sep;29(3):627-32
pubmed: 25915689
Addiction. 2020 Jul;115(7):1207-1216
pubmed: 31606008
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
J Public Health (Oxf). 2016 Mar;38(1):183-8
pubmed: 25630540
Lancet Public Health. 2017 Dec;2(12):e536-e537
pubmed: 29253435
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
BMJ. 2012 Feb 09;344:e536
pubmed: 22323502
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Clin Pharmacol Ther. 2015 Jun;97(6):541-4
pubmed: 25677377
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):274-278
pubmed: 33381640
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
J Public Health (Oxf). 2019 Jun 1;41(2):412-421
pubmed: 29860521
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
JAMA Psychiatry. 2020 Oct 1;77(10):1044-1051
pubmed: 32459328
Int J Methods Psychiatr Res. 2010 Jun;19 Suppl 1:4-22
pubmed: 20527002
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
Int J Drug Policy. 2022 Jan;99:103381
pubmed: 34465496
Nat Neurosci. 2020 May;23(5):600-610
pubmed: 32251385
Clin Pharmacol Ther. 2019 May;105(5):1139-1147
pubmed: 30703255